ProteoWise, Inc.
New Haven, US · Founded 2018 · Delaware corporation · 2 known investors
ProteoWise develops the Hyperblot benchtop instrument for high-throughput multiplexed proteomics, letting researchers load samples and antibody panels to obtain quantified western-style protein data. It targets life-science researchers working in areas such as neuroscience, cancer, and immunology.
Founders & leadership
ProteoWise, Inc. was founded in 2018 by Stephen M. Strittmatter and Misha Kostylev.
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$11.3M disclosed across 3 rounds · 2020–2024
▶$2.3MraisedDec 2024 · 6 investors · BiotechnologyRule 506(b)
- Daniel WagnerDirector
- Benjamin D. CombDirector
- Erik GuntherExecutive Officer, Director
- David SmollerDirector
- Offering amount
- $10M
- Amount sold
- $2.3M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedApr 2021 · 5 investors · BiotechnologyRule 506(b)
- Erik GuntherExecutive Officer, Director, Promoter
- Benjamin CombDirector
- Daniel WagnerDirector
- Offering amount
- $2.7M
- Amount sold
- $2.7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$6.3MraisedMar 2020 · 15 investors · BiotechnologyRule 506(b)
- Benjamin CombDirector
- Erik GuntherExecutive Officer, Director, Promoter
- Daniel WagnerDirector
- Offering amount
- $6.3M
- Amount sold
- $6.3M
- Finders' fees
- $89.7K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $251.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does ProteoWise, Inc. do?
- ProteoWise develops the Hyperblot benchtop instrument for high-throughput multiplexed proteomics, letting researchers load samples and antibody panels to obtain quantified western-style protein data. It targets life-science researchers working in areas such as neuroscience, cancer, and immunology.
- Who founded ProteoWise, Inc.?
- ProteoWise, Inc. was founded by Stephen M. Strittmatter, Misha Kostylev in 2018.
- Who are ProteoWise, Inc.'s investors?
- ProteoWise, Inc.'s investors include Connecticut Innovations, Foothill Ventures.
- How much funding has ProteoWise, Inc. raised?
- ProteoWise, Inc. has disclosed $11.3M raised across 3 rounds.
- Where is ProteoWise, Inc. headquartered?
- ProteoWise, Inc. is headquartered in New Haven, US.